| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Nektar Therapeutics (LSE: 0UNL)
0UNL Technical Analysis
5
| As on 8th Jan 2026 0UNL STOCK Price closed @ 42.90 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.55 & Strong Buy for SHORT-TERM with Stoploss of 2.31 we also expect STOCK to react on Following IMPORTANT LEVELS. |
0UNLSTOCK Price
| Open | 43.51 | Change | Price | % |
| High | 43.67 | 1 Day | -0.32 | -0.74 |
| Low | 42.90 | 1 Week | 42.02 | 4775.00 |
| Close | 42.90 | 1 Month | 41.89 | 4147.52 |
| Volume | 1034 | 1 Year | 41.78 | 3730.36 |
| 52 Week High 43.22 | 52 Week Low 0.83 | ||||
LSE UK Most Active Stocks
| ALBA | 0.02 | 0.00% |
| UKOG | 0.01 | 0.00% |
| ECR | 0.27 | -20.59% |
| BZT | 0.10 | -16.67% |
| MSMN | 0.02 | 0.00% |
| DEMG | 0.02 | -50.00% |
| RBD | 0.07 | 0.00% |
| CLON | 0.02 | 0.00% |
| SMDS | 582.50 | 0.00% |
| DKE | 0.15 | 0.00% |
LSE UK Top Gainers Stocks
LSE UK Top Losers Stocks
| 0UNL Daily Charts |
0UNL Intraday Charts |
Whats New @ Bazaartrend |
0UNL Free Analysis |
|
|
0UNL Important Levels Intraday
| RESISTANCE | 44.38 |
| RESISTANCE | 43.91 |
| RESISTANCE | 43.61 |
| RESISTANCE | 43.32 |
| SUPPORT | 42.48 |
| SUPPORT | 42.19 |
| SUPPORT | 41.89 |
| SUPPORT | 41.42 |
0UNL Forecast January 2026
| 4th UP Forecast | 44.06 |
| 3rd UP Forecast | 43.69 |
| 2nd UP Forecast | 43.46 |
| 1st UP Forecast | 43.23 |
| 1st DOWN Forecast | 42.57 |
| 2nd DOWN Forecast | 42.34 |
| 3rd DOWN Forecast | 42.11 |
| 4th DOWN Forecast | 41.74 |
0UNL Weekly Forecast
| 4th UP Forecast | 43.03 |
| 3rd UP Forecast | 42.99 |
| 2nd UP Forecast | 42.96 |
| 1st UP Forecast | 42.94 |
| 1st DOWN Forecast | 42.86 |
| 2nd DOWN Forecast | 42.84 |
| 3rd DOWN Forecast | 42.81 |
| 4th DOWN Forecast | 42.77 |
0UNL Forecast2026
| 4th UP Forecast | 127.84 |
| 3rd UP Forecast | 100.6 |
| 2nd UP Forecast | 83.76 |
| 1st UP Forecast | 66.92 |
| 1st DOWN Forecast | 18.88 |
| 2nd DOWN Forecast | 2.04 |
| 3rd DOWN Forecast | -14.8 |
| 4th DOWN Forecast | -42.04 |
Nektar Therapeutics ( LSE UK Symbol : 0UNL )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
0UNL Business Profile
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India. Address: 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service